Aptorum Group Limited (NASDAQ:APM) Sees Large Increase in Short Interest

Aptorum Group Limited (NASDAQ:APM) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 2,700 shares, an increase of 22.7% from the September 30th total of 2,200 shares. Based on an average trading volume of 15,500 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company’s shares are short sold.

Aptorum Group Stock Down 4.1 %

Shares of APM stock opened at $1.42 on Wednesday. The stock has a 50-day moving average of $2.26 and a 200-day moving average of $3.64. Aptorum Group has a one year low of $1.35 and a one year high of $17.49.

Institutional Trading of Aptorum Group

A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. bought a new position in shares of Aptorum Group Limited (NASDAQ:APM) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned approximately 0.27% of Aptorum Group as of its most recent filing with the Securities and Exchange Commission. 3.80% of the stock is owned by institutional investors.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.